Holen Sie sich die Stockscreener-App
4.00
0.73%
-0.04
Handel nachbörslich:
3.99
-0.010
-0.25%
Schlusskurs vom Vortag:
$4.04
Offen:
$4.07
24-Stunden-Volumen:
272.14K
Relative Volume:
0.62
Marktkapitalisierung:
$377.75M
Einnahmen:
$35.11M
Nettoeinkommen (Verlust:
$-79.20M
KGV:
-0.9224
EPS:
-4.3367
Netto-Cashflow:
$-88.62M
1W Leistung:
+10.18%
1M Leistung:
-2.42%
6M Leistung:
+10.18%
1J Leistung:
+29.38%
1-Tages-Spanne:
$3.97
$4.15
1-Wochen-Bereich:
$3.5801
$4.195
52-Wochen-Spanne:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Firmenname
X 4 Pharmaceuticals Inc
Sektor
Branche
Telefon
857-529-8300
Adresse
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.005 | 381.05M | 35.11M | -79.20M | -88.62M | -4.3367 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Eingeleitet | Guggenheim | Buy |
| 2025-12-05 | Fortgesetzt | Stifel | Buy |
| 2023-12-12 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-12-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-12-05 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-07 | Eingeleitet | Stifel | Buy |
| 2019-06-05 | Eingeleitet | Cowen | Outperform |
Alle ansehen
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
Torrent Pharmaceuticals Ltd. Hits All-Time High of Rs 4,698.8 as Momentum Builds Across Timeframes - Markets Mojo
Layoff Tracker: AbbVie, Novartis slash US headcount - BioSpace
Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan
Universe Pharmaceuticals (NASDAQ: UPC) CEO receives share grants under 2026 equity plan - Stock Titan
[Form 4] INOVIO PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress - Yahoo Finance
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now - sharewise.com
Can Encompass Health's Expansion Strategy Make It a Hold for Now? - TradingView
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
[EFFECT] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Perceptive group holds 7.3% of X4 Pharmaceuticals (NASDAQ: XFOR) with exercisable warrants - Stock Titan
This Insider Has Just Sold Shares In X4 Pharmaceuticals - simplywall.st
ANIP Valuation: Does 9.8x Forward P/E Offer Upside? - TradingView
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger - Stock Titan
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Biogen buys Apellis (APLS) for $41 cash plus CVR per share - Stock Titan
Biogen to acquire Apellis (NASDAQ: APLS) for $41 per share plus CVR - Stock Titan
Biogen deal: Apellis (APLS) director’s shares and options cashed out - Stock Titan
Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap - Stock Titan
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now - Yahoo Finance
X4 Pharmaceuticals (XFOR) corrects director nominee and expands equity plan - Stock Titan
X4 Pharma CFO Kirske sells $72,820 in common stock - Investing.com
X4 Pharmaceuticals (XFOR) CFO sells shares to cover tax obligation - Stock Titan
[144] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Shareholders at X4 Pharmaceuticals (NASDAQ: XFOR) approve equity plan - Stock Titan
5 Unrivaled Penny Stocks to Buy Now - Insider Monkey
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
XFOR (X4 Pharmaceuticals) beats Q1 2026 EPS estimates by 21.6 percent, shares climb 3 percent.Collaborative Trading Signals - newser.com
How X4 Pharmaceuticals (XFOR) is positioning for the next five years (Bearish Sentiment) 2026-05-08Shared Momentum Picks - newser.com
Major holder Artal group converts LXRX (LXRX) Series B preferred into 20.4M common shares - Stock Titan
Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
CapEx per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
EBIT per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
X4 pharmaceuticals incmay offer up to $300 million of common stock, preferred stock, debt securities, warrants, and/or unitsSEC filing - marketscreener.com
X4 Pharmaceuticals IncMay Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or UnitsSEC Filing - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) files $300M shelf; $75M ATM with Jefferies - Stock Titan
X4 Pharmaceuticals, Inc. Q1 2026 Financial Results and Forward-Looking Statements – Quarterly Report Highlights - Minichart
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
X4 Pharmaceuticals: Q1 Earnings Snapshot - KING5.com
X4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI - Quiver Quantitative
EU authorizes first WHIM syndrome treatment as X4 trial nears enrollment - Stock Titan
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
EU approves XOLREMDI as X4 Pharmaceuticals (NASDAQ: XFOR) reports Q1 loss - Stock Titan
X4 Pharmaceuticals Inc (XFOR) - MSN
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA - ACCESS Newswire
Regeneron Pharmaceuticals (REGN) director sells 100 shares under 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Business Wire
Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):